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Abstract.  
Proteinase-activated receptor-2 (PAR2) is widely expressed in the CNS but whether it plays a 
key role in inflammation-related behavioural changes remains unknown.  Hence, in the 
present study we have examined whether PAR2 contributes to behaviour associated with 
systemic inflammation using PAR2 transgenic mice.  The onset of sickness behaviour was 
delayed and the recovery accelerated in PAR2-/- mice in the LPS-induced model of sickness 
behaviour. In contrast, PAR2 does not contribute to behaviour under normal conditions.  In 
conclusion, these data suggest that PAR2 does not contribute to behaviour in the normal 
healthy brain but it plays a role in inflammation-related behavioural changes.  
 
Keywords: Proteinase-activated receptor-2; LPS; sickness behaviour; locomotor activity; 
anxiety; sucrose preference. 
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1. Introduction 
Proteinase-activated receptors (PARs) are a novel class of GPCRs that are unique in their 
activation, whereby the cleavage of the N-terminus by a serine proteinase unveils a sequence 
WKDWDFWVDVD³WHWKHUHG-OLJDQG´7KH³WHWKHUHG-OLJDQG´ELQGVWRWKHVHFRQGH[WUDFHOOXODUORRS
of the receptor, leading to the activation of the receptor. To date, four members of the PAR 
family have been cloned, namely PAR 1-4. Of these, PAR1, 3 & 4 are preferentially activated 
by thrombin, whereas trypsin and trypsin-like proteinases are proposed to preferentially 
activate PAR2 (MacFarlane et al., 2001; Adams et al., 2011; Ramachandran et al., 2012), 
although within the central nervous system (CNS), the endogenous activators for PARs 
remain speculative. Several selective PAR-activating peptides have been developed to probe 
the distinct functions of each receptor, although evidence suggests diligence is required when 
using such agonists and their use for CNS investigations in vivo is limited due to poor 
bioavailability (Ramachandran et al., 2012). To overcome these issues, novel non-peptidic 
agonists, including AC-264613 and GB110, with high potency and good stability have been 
developed (Gardell et al., 2008; Barry et al., 2010). 
Despite PAR2 being expressed in neurones, astrocytes, microglia and oligodendrocytes 
within both the human and rodent CNS (Noorbakhsh et al., 2003; Bushell, 2007), there 
remains a large void in our knowledge as to the functional role of PAR2 in the brain.  
Evidence from both human and experimental models has implicated PAR2 in CNS disorders 
LQFOXGLQJ$O]KHLPHU¶VGLVHDVH (AD), HIV dementia, multiple sclerosis and stroke (Jin et al., 
2005; Noorbakhsh et al., 2005, 2006).  However, much of this is indirect in the form of 
observed alterations in PAR2 expression rather than evidence of an active role in disease 
pathogenesis per se. Indeed, data suggest that PAR2 activation can be protective or pro-
degenerative depending on the cell type (neurones or astrocytes) where increased expression 
is observed (Bushell, 2007; Jin et al., 2005; Noorbakhsh et al., 2005, 2006).  Recent studies, 
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including those from our laboratory, have provided direct functional evidence that PAR2 
activation is neuroprotective, an effect mediated indirectly via astrocytic activation, 
chemokine release and inhibition of MAPK signalling (Wang et al., 2007; Greenwood and 
Bushell, 2011).  Furthermore, we and others have previously shown in primary hippocampal 
cultures that PAR2 activation evokes physiological elevations in intracellular calcium (Ca2+) 
through the Gq / PLC pathway (Wang et al., 2002; Bushell et al., 2006) and we were recently 
the first to report that PAR2 activation modulates hippocampal neuronal excitability and 
synaptic transmission in vitro (Gan et al., 2011).  Interestingly, despite the presence of PAR2 
on neuronal populations, this modulation of neuronal excitability and synaptic transmission 
appears indirect and mediated via astrocytic activation. This mirrors the neuroprotective role 
of PAR2 which is also primarily mediated via astrocytic activation.   
However, despite PAR2 activation modulating synaptic activity and being neuroprotective in 
in vitro preparations, whether PAR2 plays a key role in behaviour examined in the normal 
brain under healthy conditions or under conditions favourable for its activation remains 
unknown.   Hence, in the present study, we have utilised F2RL1 genetically modified mice to 
examine the contribution of PAR2 to inflammation-related behavioural changes and to 
locomotor activity, anxiety- and anhedonic-like behaviour and spatial reference memory 
under normal conditions. Our novel findings indicate that PAR2 contributes to inflammation-
related changes in behaviour and that the role of PAR2 in inflammation-related CNS 
disorders should be examined further to fully elucidate its therapeutic potential.  
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2. Materials and Methods 
2.1. Animals 
F2RL1 genetically modified mice (PAR2+/+, PAR2+/- and PAR2-/-), which are bred on a 
C57BL/6J background, were obtained from multiple crossings of 14 pairs of PAR2+/- mice 
which were supplied by Professor R. Plevin, University of Strathclyde (Ferrell et al., 2003). 
C57BL/6J mice used for vehicle control experiments were obtained from in house colonies 
from the Biological Procedures Unit, University of Strathclyde.  All mice were 12 weeks old 
at the commencement of behavioural testing. They were housed at 21±2 ºC and 45-55% 
humidity, with a 12/12 hours light/dark cycle (lights on at 0600, off at 1800). Mice were 
group-housed according to genotype (housed 3-10 per cage depending on availability but 
testing was performed on a minimum of 6 mice per genotype per run) except where required 
to be singly housed for the purposes of the experiment, provided with environmental 
enrichment in the form of plastic huts and nesting material, and given ad libitum food and 
water. Procedures were in compliance with the requirements of the UK Animals (Scientific 
Procedures) Act 1986. In all experiments, mice were handled on the day prior to the 
beginning of testing to habituate the animals to the tester and all data is generated from 
repeated experiments of at least two cohorts of mice. 
2.2. Behavioural testing 
Testing in the open field test (OFT), elevated plus-maze (EPM) and the Morris water maze 
(MWM) was carried out on 48 males (26.0 ± 0.4g; n=16 for all 3 genotypes), during the light 
cycle. 
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2.2.1. Open field test 
Mice were placed in the centre of an open field 40 x 40 x 40cm (lighting 45 lux)  made from 
black infrared light (IR)-translucent Perspex placed on an in IR light box (Tracksys, 
Nottingham, UK). Total distance moved and entries into and time spent in a 14 x 14 cm 
centre square were recorded for 10 min by tracking software (Ethovision, Noldus, 
Netherlands). 
2.2.2. Elevated plus-maze 
 Mice were placed in the centre (45 lux) of a plus-shaped maze with two open (30 x 5cm, 60 
lux) and two closed arms (30 x 5cm, 15 cm walls, 6 lux) made of IR-translucent Perspex with 
integral IR light sources elevated 70cm from the floor (Tracksys, Nottingham, UK). Entries 
into each type of arm were recorded for 10 min by Ethovision software (Noldus, Netherlands) 
and the total number of entries, % open arm entries and % open arm time calculated. 
 
2.2.3. Morris Water Maze 
Mice were tested in a 98 cm diameter maze containing water at 21ºC with a transparent 10 
cm diameter submerged platform, in a room (45 lux) with extra-maze cues. 3-4 times daily 
for 5 days, mice were released at one of 4 randomly varied points, and swam until they 
located the platform. Platform location remained constant for each mouse.  On the final trial 
of day 5, the platform was removed and mice allowed to swim for 60s (probe test). Time 
spent in the quadrant of the previous location of the platform (target quadrant) and the 
opposite quadrant was recorded.  
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2.2.4. Sucrose preference test 
Prior to the test, each mouse was singly housed and each cage was supplied with two bottles 
of tap water. The amount of water drunk was measured daily by weight for two consecutive 
days in order to determine which bottle position, either left or right, was preferred. The 
sucrose preference test was started by replacing the water bottle in the non-preferred position 
with an identical bottle containing 1% sucrose solution. On subsequent days the position of 
the two bottles was randomly determined to avoid a place preference. The amount of water 
and sucrose consumed was measured daily over the whole experimental period and the 
VXFURVHGUXQNFDOFXODWHG'DLO\IRRGLQWDNHDQGERG\ZHLJKWZDVDOVRPHDVXUHGRYHUWKH
ZKROHSHULRG 
2.2.5. LPS-induced sickness behaviour 
LPS-induced sickness behaviour was investigated in 39 male mice (27.7 ± 0.6g; PAR2+/+ 
n=12, PAR2+/- n=11, PAR2-/- n=9, vehicle controls n=7). On day 1, mice were handled and on 
day 2 they were singly housed with two water bottles. Sucrose preference testing (SPT) was 
then carried out over days 4-7. On day 8, baseline parameters of the OFT, SPT, food intake 
and body weight were measured. On day 9, mice were injected with either LPS (1 mg kg-1 in 
PBS; extracted from S. Enteritidis, Sigma-Aldrich, UK, Cat No. L6011) or PBS alone 
(vehicle) and OFT, SPT, food intake and body weight parameters measured at baseline prior 
to injection and 0 , 2 , 24, 48 and 72h post LPS injection. Baseline measurements were taken 
in the morning at 10.00. 
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2.3. Quantitative RT-PCR 
2.3.1. LPS injection 
C57BL/6J male mice (10-12 weeks old) were given a single injection of either LPS (1 mg kg-
1
 in PBS) or PBS alone and the cerebellum, hippocampus and hypothalamus collected either 
2 hours (PBS n=5, LPS n=4) or 24 hours (n = 5 per group) post injection and stored in 
RNAlater tissue storage solution (Life Technologies, Paisley, UK) at <4oC until processing.   
2.3.2. RNA isolation and reverse transcription 
Total RNA was isolated from rodent brain regions using the RNeasy Lipid Tissue Mini Kit 
(QIAGEN Ltd, Manchester, UK) standard protocol, then DNased using the TURBO DNA-
free kit (Life Technologies Ltd., Paisley, UK). 500ng RNA was reverse transcribed using the 
ImProm-II Reverse Transcription System (Promega UK, Southampton, UK) with random 
primers (0.5 mg; 6.0 mM MgCl2) in a 20µL reaction volume, which was subsequently diluted 
to 100µL with water to provide cDNA template for realtime PCR. Negative water blank and -
RT controls were used throughout. 
2.3.3. Real-time PCR 
Cycle threshold (Ct) values were generated on an ABI 7900 HT Prism Sequence Detection 
System (Applied Biosystems, Foster City, CA, USA) using the Universal ProbeLibrary 
(UPL) System (Roche Applied Science) and ABsolute QPCR ROX Mix (Abgene). qRT-PCR 
results were analysed using the relative quantifLFDWLRQPHWKRGRIFRPSDUDWLYH&Wǻǻ&W), 
with E-Actin DFWLQJDVWKHFDOLEUDWRURUµKRXVHNHHSLQJ¶JHQHIRUmouse and rat samples and 
GAPDH for human samples. Expression of the calibrator genes was stable and did not differ 
significantly between control and treatment groups (data not shown). All assays were 
designed using the online ProbeFinder software (lifescience.roche.com) to generate primer 
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sequences (Table 1), except for mouse E-actin, which used the commercially-available 
Universal Probe Library Mouse ACTB Gene Assay (Roche). Each reaction contained 100nM 
of the relevant Universal Probe, 400nM of each primer, 2µl diluted cDNA and 5.0µl 
ABsolute QPCR ROX Mix (VWR International, Lutterworth, UK) in a final volume of 10µl. 
Reactions were run in triplicate, with the mean Ct value from the three reactions used for 
subsequent data analysis.  
2.4. Statistics 
$OOGDWDDUHH[SUHVVHGDVPHDQ6(0'DWDZHUHFRPSDUHGE\SDLUHGRUXQSDLUHG6WXGHQW¶V
t-tests, one-ZD\DQDO\VLVRIYDULDQFHZLWK7XNH\¶V comparison or 2-way mixed-model 
ANOVA followed by Bonferroni post-hoc comparisons as appropriate. Differences were 
considered significant when P<0.05.    
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3. Results  
3.1. PAR2 contributes to LPS-induced sickness behaviour  
PAR2 is proposed to play a role in several CNS and peripheral diseases whose aetiology and 
SDWKRORJ\DUHFORVHO\OLQNHGWRLQIODPPDWLRQLQFOXGLQJ$O]KHLPHU¶VGLVHDVH (AD), Multiple 
Sclerosis (MS) and rheumatoid arthritis (Ferrell et al., 2003; Noorbakhsh et al., 2006; 
Afkhami-Goli et al., 2007).  Hence, we used the LPS-induced sickness behaviour model of 
systemic infection to examine whether PAR2 is involved in a number of the behavioural 
changes associated with activation of the immune system. 
3.1.1. Open field test. 
In the OFT, LPS injection (1mg kg-1) resulted in a significant reduction in locomotor activity 
over the first 24 h after injection compared to vehicle-injected controls (2h post injection, 
p<0.001 for all 3 genotypes vs vehicle control), which returned to levels similar those 
observed in vehicle-injected controls by 72 h (p>0.05 for all 3 genotypes vs vehicle control, 
Figure 1A). However,  PAR2-/- mice showed significantly increased locomotion at 24 h and 
48 h post injection compared with PAR2+/+ (24 h: F(2,29)=4.269, p=0.0237, PAR2+/+ versus 
PAR2-/-
 
p=0.0217; 48h: F(2,29)=3.960 p=0.0301, PAR2+/+ versus PAR2-/- p=0.0217, Figure 
1A).  Furthermore, the number of entries into the centre square at 24 h post injection was 
increased in PAR2-/- mice when compared with PAR2+/+ (F(2,29)=3.727, p=0.0362, PAR2+/+ 
versus PAR2-/-
 
p=0.0282, Figure 1B).  With regard to time spent in the centre square, 
following LPS injection, no differences were observed between genotypes at any time point 
investigated. 
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3.1.2. Sucrose preference test. 
Another behavioural characteristic associated with sickness behaviour is the induction of 
anhedonia.  We therefore used the sucrose preference test to investigate whether PAR2 
contributes to the induction and maintenance of anhedonia under these experimental 
conditions.  All mice showed a sucrose preference over the 3 days prior to LPS injection with 
no significant differences observed over the 3 days (F(2,60)=0.327,  p=0.723) or between 
genotypes (F(2,30)=0.072,  p=0.931, Figure 2A).  Similarly, no effect of day (F(2,58)=0.097, 
p=0.908) or genotype (F(2,29)=1.948,  p=0.161, Fig 2B) were seen in the total fluid drunk.  
These data indicate that PAR2 plays no role in sucrose preference or fluid intake in normal 
healthy mice and therefore we can use this model to investigate the role of PAR2 in LPS-
induced anhedonia. 
The effect of LPS injection on the % sucrose drunk was significantly reduced in the first 2 h 
post injection (F(2,29)=3.751, p=0.035, PAR2+/- versus PAR2-/-  p=0.035, PAR2+/+ versus 
PAR2-/-
 
p=0.119). Thus, the onset of anhedonia is delayed in the PAR2-/- mice when 
compared to PAR2+/- mice and shows a trend towards a delay when compared to PAR2+/+ 
mice (Figure 2C).  
3.1.3. Food intake and change in body weight. 
We also examined whether PAR2 deletion contributes to the changes in food intake and body 
weight associated with sickness behaviour. No difference in initial body weight and food 
intake was observed between all three genotypes and the vehicle control group prior to LPS 
injection (p>0.05 for all 4 groups for both measures, data not shown) whereas food intake 
was significantly increased in PAR2+/- mice compared to PAR2+/+ 48h post injection. At the 
same time point PAR2-/- mice also showed a trend towards increased food intake. 
(F(2,29)=5.480, p=0.010, PAR2+/- versus PAR2+/+ p=0.010, PAR2-/- versus PAR2+/+ p=0.086, 
12 
 
Figure 3A).   Furthermore, the % change in body weight was significantly less in PAR2-/- 
mice at both 48h and 72h post injection when compared to PAR2+/+ mice (48 h: F(2,29)=3.309, 
p=0.051, PAR2-/- versus PAR2+/+ p=0.040; 72 h: F(2,29)=3.806, p=0.034, PAR2-/- versus 
PAR2+/+ p=0.027, Figure 3B). The effect of LPS on total fluid intake also differed between 
genotypes (F(2,29)= 9.000, p=0.001). PAR2-/- mice drank significantly more total fluid than 
PAR2+/+ (p=0.004) and PAR2+/- (p=0.001) in the first 2 h post injection (data not shown), 
which may be part of a more robust response to inflammation.     
3.1.4. Habituation  
In order to confirm that habituation does not contribute to the observed changes in behaviour, 
we conducted control experiments using the same time schedule as in the LPS experiment to 
examine the effect of habituation to repeated testing  in the OFT. No significant effect of 
habituation on the OFT was observed, which indicates that effects seen in LPS-injected mice 
are those of LPS alone and not habituation. 
3.2. PAR2 expression is unaltered under inflammatory CNS conditions.  
Having established that PAR2 contributes to LPS-induced sickness behaviour and associated 
food intake and body weight changes, we examined whether CNS PAR2 expression was 
altered following LPS injection. PAR2 mRNA was detected in the three brain regions 
examined, the hypothalamus, hippocampus and the cerebellum obtained from control mice 
(PBS injection) and mice exposed to a single LPS injection (1mg kg-1).  Two hours post-
injection, a time point at which behavioral changes were observed, no significant difference 
in PAR2 mRNA levels was observed in the hypothalamus (PBS ǻCt=10.1±0.4 (n=5) vs LPS 
ǻCt=9.9±0.2 (n=4); p=0.79, Figure 4A), the hippocampus (PBS ǻCt=8.4±0.2 (n=5) vs LPS 
ǻCt=8.3±0.4 (n=4); p=0.91, Figure 4A) or the cerebellum (PBS ǻCt=9.4±0.2 (n=5) vs LPS 
ǻCt=9.4±0.3 (n=4); p=0.91, Figure 4A).  In contrast, mRNA levels for the inflammatory 
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cytokines interleukin (IL)-ȕDQGtumour necrosis factor (TNF)-ĮDUHVLJQLILFDQWO\LQFUHDVHG
in all three brain regions (p<0.01 for all regions, Figure 4A).  Similarly, no significant 
difference in PAR2 mRNA levels was observed 24 hours post-injection between control mice 
and those exposed to a single LPS injection (1mg kg-1) in the hypothalamus (PBS 
ǻCt=10.7±0.2 vs. LPS ǻCt=10.3±0.8; p=0.62, each group n=5, Figure 4B), the hippocampus 
(PBS ǻCt=10.8±0.6 vs. LPS ǻCt=11.1±0.4; p=0.75, each group n=5, Figure 6B) and the 
cerebellum (PBS ǻCt=10.5±0.4 vs. LPS ǻCt=9.5±0.1; p=0.08, each group n=5, Figure 4B).  
IL-ȕp=0.04) and TNF-Įp=0.03) mRNA levels were significantly increased in the 
hypothalamus 24 hours post LPS injection as was TNF-Įp=0.02) in the cerebellum but no 
significant changes were evident in all other samples 24 hours post LPS injection.   
3.3. PAR2 deletion does not alter locomotor activity, anxiety-like behaviour or spatial 
memory.  
3.3.1. Open field test. 
General locomotor activity as measured by the distance moved over the testing period was 
unaffected (F(2,45)=0.523, p=0.596, Figure 5A) as was the number of entries into the centre 
square (F(2,45)=1.690, p=0.196, Figure 5B).  However, PAR2+/- mice spent significantly more 
time in the centre square compared to both PAR2+/+ and PAR2-/- mice (F(2,45)=8.718,  
p=0.0006, PAR2+/- vs. PAR2+/+ p=0.005, PAR2+/- vs. PAR2-/- p=0.001, PAR2+/+ vs. PAR2-/- 
p=0.827, Figure 5C) indicating that PAR2+/- mice may be less anxious under these 
behavioural conditions. 
3.3.2. Elevated Plus Maze. 
PAR2 deletion did not affect anxiety-like behaviour in the EPM test as no significant 
differences were observed between genotypes in the % time spent in open arms (F(2,46)= 
14 
 
0.261, p=0.771, Figure 5D) , % open arm entries (F(2,47)=0.114, p=0.893, Figure 5E) and the 
number of total entries (F(2,47)=0.763, p=0.472, Figure 1F) over the 10 min test period.   
3.3.3. Morris water maze. 
As we have previously shown that PAR2 activation induces a form of hippocampal synaptic 
plasticity in vitro (Gan et al., 2011), we examined whether PAR2 plays a role in spatial 
memory formation using the MWM. There was a significant effect of day in both latency to 
locate platform (F(4,180)=50.036, p=0.0005, Figure 6A) and distance travelled to the platform 
(F(4,180)= 50.1, p=0.0005, Figure 6B) over the 5 consecutive testing days.  However, there was 
no significant effect of genotype and no interaction between day and genotype in both latency 
to locate platform (genotype: F(2,42)=0.716, p=0.494,interaction: F(8,180)=0.178, p=0.994, 
Figure 6A) and distance travelled (genotype: F(2,42)=0.372, p=0.692, interaction: 
F(8,180)=0.328, p= 0.954, Figure 6B ).  In addition, during a subsequent probe test mice spent 
significantly more time in the  target quadrant compared to that spent in the opposite quadrant 
(p<0.001 for all genotypes) but there was no significant difference between genotypes 
(F(2,44)=1.517; p=0.230, Figure 6C). These data indicate that PAR2 deletion has no 
deleterious effect on spatial reference memory. 
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4. Discussion 
In the present study, we show for the first time that PAR2 contributes to the onset and 
maintenance of LPS-induced sickness behaviour whereas, in contrast, our data suggests that 
PAR2 does not contribute to locomotor activity and anhedonic-like behaviour under normal 
healthy conditions.  In addition, we show that under neuroinflammatory conditions within the 
CNS, no change in PAR2 expression is observed indicating that PAR2 activation per se 
contributes to inflammation-induced changes in behaviour rather than altered expression. 
4.1. PAR2 activation participates in the onset and maintenance of sickness behaviour. 
PAR2 has been reported to be extensively expressed within the CNS from both rodent and 
human tissue, with a strong link to inflammation-related diseases (Bushell, 2007; 
Ramachandran et al., 2012). Hence, we examined the role of PAR2 in behavioural tests in 
which the conditions for its activation were favourable.  It has been suggested that PARs may 
become activated under inflammatory conditions where the blood brain barrier (BBB) 
becomes leaky (Gingrich and Traynelis, 2000; Bushell, 2007), hence we utilised a well-
established model of systemic infection that is used extensively to examine the role of 
inflammatory mediators on behaviour, namely LPS-induced sickness behaviour (Dantzer et 
al., 2008; McCusker and Kelly, 2013).  Sickness behaviour can be measured using a number 
of parameters and we focused on locomotor activity and the induction of anhedonia as well as 
changes in food intake and body weight.  Our data shows that sickness behaviour was 
induced post LPS injection in all genotypes tested but deficits in its induction and 
maintenance was apparent in PAR2-/- mice.  Indeed in the SPT, the decrease in sucrose 
preference was delayed in PAR2-/- mice post LPS injection whereas in the OFT, an increased 
recovery in distance moved and entry into centre squares was observed in PAR2-/- mice post 
LPS injection. Furthermore, the decrease in body weight was significantly reduced 24 and 72 
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hours post injection.  These data suggest for the first time that PAR2 contributes to the onset 
and maintenance of LPS-induced sickness behaviour when examined using these 
characteristic behavioural outcomes associated with sickness behaviour.  So how is PAR2 
involved? Our understanding of brain-immune interactions has developed significantly since 
the brain was thought to be an immune privileged site. It is suggested that peripheral 
infections and the inflammatory cytokines this induces cross the leaky BBB leading to the 
behavioural symptoms associated with sickness with recent evidence also indicating that 
these pro-inflammatory cytokines are also synthesised within the brain during systemic 
infections (Dantzer et al., 2008; Cunningham et al., 2009; Schedlowski et al., 2014).  Some of 
the main protagonists suggested to underlie the observed behavioural changes include the 
pro-inflammatory cytokines IL-ȕIL-6 and 71)Įwith numerous studies confirming that 
these cytokines are increased following systemic infections as well as their direct application 
to the brain leading to changes in behaviour similar to those seen in sickness behaviour 
(Montkowski et al., 1997; Bluthé et al., 2000; Cunningham et al., 2009; McCusker and Kelly, 
2013). Following this causal link between pro-inflammatory cytokines and sickness 
behaviour, a recent study revealed a link between LPS, the induction of the pro-inflammatory 
cytokine IL-32 and PAR2 activation (Nakayama et al., 2013).  Indeed LPS significantly 
increased IL-32 production in THP-1 cells which in turn up-regulated proteinase-3 activity 
OHDGLQJWR3$5DFWLYDWLRQDQG71)ĮSURGXFWLRQ  In addition, there is evidence that LPS 
induces elevated levels of other potential endogenous PAR2 activators (Scarisbrick et al., 
2006 and Kirshenbaum et al., 2008) but whether these contribute to the role of PAR2 in the 
onset and maintenance of sickness behaviour either by crossing the BBB or by induction of 
their production within the brain itself requires further investigation.  In addition to LPS 
resulting in sickness-like behaviour, administration of LPS has also been shown to impair 
cognitive function as evidenced in tests of avoidance learning (Sparkman et al., 2005a), 
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contextual fear conditioning (Pugh et al., 1998; Kranjac et al., 2012), novel object recognition 
(Miwa et al., 2011) and spatial memory tests (Shaw et al., 2001; Sparkman et al., 2005b) as 
well as exacerbating memory deficits in a mouse model of delirium (Field et al., 2012; 
Griffin et al., 2013).   Whilst not the focus of the present study, one could speculate that 
PAR2 deletion may also impair LPS-induced cognitive deficits and indeed this warrants 
further investigation.  
4.2. Neuroinflammatory conditions do not result in increased PAR2 expression.   
We have shown a role for PAR2 in LPS-induced sickness behaviour, hence we sought to 
determine whether PAR2 expression was up-regulated during LPS-induced sickness 
behaviour.  Our data indicates that PAR2 mRNA expression remains unaltered following 
LPS injection both acutely and after 24 hrs thus suggesting that changes in PAR2 expression 
do not account for the changes in sickness behaviour observed in PAR2-/- mice.  Our findings 
are in contrast to a number of studies that have shown that LPS as well as IL-ȕDQG71)Į
can lead to increased PAR2 expression in a variety of preparations (Hamilton et al., 2001; 
Morello et al., 2005; Ritchie et al., 2007).  However, given increased PAR2 expression in 
these studies was observed in in vitro preparations rather than in vivo as per the current study, 
direct comparisons are difficult.  Thus our data implies that activation of PAR2 per se 
accounts for the role of PAR2 in sickness behaviour but the exact identity of the PAR2 
activator(s) remains to be determined with several potential candidates and mechanisms by 
which this may occur outlined above.  
4.3. PAR2 does not contribute to behaviour under normal conditions. 
We have recently shown that PAR2 activation indirectly modulates hippocampal neuronal 
excitability and synaptic transmission via astrocytic activation (Gan et al., 2011). However, 
whether PAR2 contributes to CNS function and behaviour under normal conditions is 
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unknown.  Hence we utilised PAR2-/- mice to investigate its contribution to behaviour using 
standard tests for locomotor activity, anxiety-like behaviour, spatial memory and anhedonic-
like behaviour.  Our data reveals that PAR2 does not contribute to behavioural characteristics 
associated with these tests as behaviour in PAR2-/- mice was not altered in the OFT, EPM, 
MWM or SPT when compared to PAR2+/+ controls.  Whether an endogenous PAR2 activator 
released from resident cells present within the CNS remains to be elucidated with several 
candidates being proposed including mast cell tryptase, trypsinogen IV and kallikreins 
(Steinhoff et al., 2000; Noorbakhsh et al. 2005, 2006; Hollenberg et al., 2008) but our data 
indicates that PAR2 does not contribute to these behavioural paradigms in the normal healthy 
brain.  Similar findings have been reported for another member of the PAR family, PAR1, 
with behaviour in PAR1-/- mice being unaltered in tests of locomotor activity and anxiety-like 
behaviour.  However, PAR1-/- mice displayed deficits in emotionally motivated behavioural 
learning when examined using the passive avoidance task and in cued fear conditioning 
(Almonte et al., 2007). In addition, a recent study has revealed that a shift in G-protein 
signalling is a novel mechanism by which PAR1 modulates emotionally motivated 
behavioural learning in the amygdala (Bourgognon et al., 2013). The role of PAR1 has been 
further implicated in learning and memory with recent studies highlighting deficits in 
hippocampal-dependent learning and synaptic plasticity in PAR1-/- mice compared to their 
littermate controls (Almonte et al., 2013). These findings indicate that PAR1 and PAR2 are 
not involved in locomotor activity and anxiety-like behaviour but implicate PAR1 in learning 
and memory. No deficits were apparent in PAR2-/- mice in the MWM, suggesting no role in 
spatial memory but whether PAR2 contributes to emotionally motivated behavioural learning 
remains to be elucidated and is beyond the scope of this study. 
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4.4. Conclusions 
In conclusion, we have found that PAR2 contributes to the onset and maintenance of LPS-
induced sickness behaviour but does not contribute to locomotor, anxiety-like behaviour and 
spatial memory under normal healthy conditions. We suggest that a change in PAR2 
expression within the CNS does not underlie our observations in sickness behaviour and is 
not evident under chronic inflammatory conditions such as obesity and AD.  Further work is 
required to fully elucidate the mechanisms and signalling pathways underlying the role of 
PAR2 in sickness behaviour and to determine whether PAR2 plays a significant role in other 
conditions where changes in the inflammatory environment are observed. 
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Figure legends 
Figure 1. PAR2 contributes to the onset and maintenance of LPS-induced sickness 
behaviour. PAR2-/- mice recovered significantly more quickly from LPS-induced 
behavioural deficits compared to both PAR2+/+ as shown by A) an increased distance moved 
at 24 and 48 hrs post LPS injection and B) increased entries into the centre square 24 hrs post 
LPS injection. # = P<0.05 vs vehicle, * = P<0.05 vs PAR2+/+1IRUDOOPLFH 
Figure 2. Induction of anhedonia is delayed in PAR2-/- mice following LPS injection.  A) 
Sucrose preference and B) fluid intake are similar in all 3 genotypes tested in the SPT.    C) 
Anhedonia induction is delayed in PAR2-/- mice compared to PAR2+/+ and PAR2+/- mice as 
shown by sucrose preference being maintained in the first 2 hrs post LPS injection. * = 
P<0.05 vs PAR2+/-1IRUDOOPLFH 
Figure 3. Food intake and body weight changes are reduced following LPS injection. A) 
Food intake recovers more quickly in PAR2+/- mice compared to PAR2+/+ controls at 48h post 
LPS injection with a trend towards a recovery seen in PAR2-/- mice. B) Body weight recovers 
more quickly in PAR2-/- mice compared to PAR2+/+ controls at 48 and 72h post LPS 
injection. # = P<0.05 vs vehicle, * = P<0.05 vs PAR2+/+1IRUDOOPLFH  
Figure 4. PAR2 mRNA expression remains unchanged in conditions associated with 
neuroinflammation. A) PAR2 mRNA levels are unaltered but IL-ȕDQG71)-ĮP51$
levels are increased 2 hours post injection in all 3 brain regions examined. B) PAR2 mRNA 
levels are unchanged 24 hours post LPS injection but elevated IL-ȕDQG71)-ĮP51$
levels are maintained in the hypothalamus.  * = P<0.05 vs control, ** = P<0.01 vs control, 
*** = P<YVFRQWUROQIRUDOOWLVVXHWHVWHG 
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Figure 5. PAR2 does not contribute to locomotor activity and anxiety-like behaviour.  
A-C) No significant differences were observed on the total distance moved and entries into 
the centre square between all 3 PAR2 genotypes tested in the OFT. However, PAR2+/- mice 
spent significantly more time in the centre square compared to both PAR2+/+ and PAR2-/- 
mice.  D-F) No changes in performance were observed for time in open arms, open arm 
entries or total arm entries for all 3 genotypes tested in the EPM. ** = P<0.01 vs both 
PAR2+/+ and PAR2-/-. N=16 for all genotypes.  
Figure 6. PAR2 deletion does not affect performance in a spatial reference memory 
task. No difference in performance was observed for all 3 genotypes in the MWM as gaged 
by A) latency to locate the platform, B) distance travelled to locate the platform and C) time 
spent in the target vs opposite quadrant. *** = P<0.001 vs target quadrant. N=16 for all 
genotypes. 
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